Literature DB >> 8339811

The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom.

I D Johnston1, S A Gomm, S Kalra, A A Woodcock, C C Evans, C R Hind.   

Abstract

The case notes of 200 patients with cryptogenic fibrosing alveolitis, from three regions in the United Kingdom, were reviewed, in order to determine how physicians manage this uncommon condition. In the majority of cases (119), the diagnosis was based solely on clinical grounds, with no attempt at histological confirmation of the diagnosis. Transbronchial biopsy was attempted in 66 patients, but was unhelpful in confirming a diagnosis of pulmonary fibrosis in 30% of these patients. Thirty five patients underwent bronchoalveolar lavage, and 15 had an open lung biopsy. Of the 132 patients treated, 110 received prednisolone alone, and the rest a combination of other immunosuppressive agents. The doses and duration of therapy varied considerably. These results suggest that, in the late 1980s, there were wide variations of practice in the management of cryptogenic fibrosing alveolitis in the United Kingdom. This is likely to reflect a paucity of information on the optimum management of this uncommon condition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339811

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis.

Authors:  J Britton
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

4.  A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis.

Authors:  M Clark; B Cooper; S Singh; M Cooper; A Carr; R Hubbard
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 5.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.

Authors:  Harold R Collard; James E Loyd; Talmadge E King; Lisa H Lancaster
Journal:  Respir Med       Date:  2007-05-16       Impact factor: 3.415

7.  British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

Authors:  I D Johnston; R J Prescott; J C Chalmers; R M Rudd
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

8.  Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP).

Authors:  N Mogulkoc; M H Brutsche; P W Bishop; B Murby; M S Greaves; A W Horrocks; M Wilson; C McCullough; M Prescott; J J Egan
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 9.  Oxidants/antioxidants in idiopathic pulmonary fibrosis.

Authors:  W MacNee; I Rahman
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

10.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.